Loading…

p53 and disease progression in patients with non-small cell lung cancer

Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight c...

Full description

Saved in:
Bibliographic Details
Published in:Surgical oncology 1995-06, Vol.4 (3), p.157-161
Main Authors: Sauter, E.R., Gwin, J.L., Mandel, J., Keller, S.M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3
cites cdi_FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3
container_end_page 161
container_issue 3
container_start_page 157
container_title Surgical oncology
container_volume 4
creator Sauter, E.R.
Gwin, J.L.
Mandel, J.
Keller, S.M.
description Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53% of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread ( P = 0.06), and p53 expression correlated significantly ( P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC.
doi_str_mv 10.1016/S0960-7404(10)80020-9
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77704943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0960740410800209</els_id><sourcerecordid>77704943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3</originalsourceid><addsrcrecordid>eNqFkE9PAyEQxYnR1Fr9CE04GT2sDuwusCdjGq0mTTyoZ0JhWjEtW2Gr8dtL_6RXL0DmvZk3_AgZMrhhwMTtKzQCCllBdcXgWgFwKJoj0mdKNkVZcjgm_YPllJyl9AkAQnLWIz1ZK86U6pPxqi6pCY46n9AkpKvYziOm5NtAfaAr03kMXaI_vvugoQ1FWprFglrMx2Id5tSaYDGek5OZWSS82N8D8v748DZ6KiYv4-fR_aSwpYCuMA4rzk3jKuYUn-LMMYsSp1kUdcWEYNOZaxpW54eTAhnwSkklUSiuSmnLAbnczc17fq0xdXrp02YZE7BdJy2lhKqpymysd0Yb25QizvQq-qWJv5qB3gDUW4B6Q2dT2gLUTe4b7gPW0yW6Q9eeWNbvdjrmX357jDrZTMii8xFtp13r_0n4A3S0fs4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77704943</pqid></control><display><type>article</type><title>p53 and disease progression in patients with non-small cell lung cancer</title><source>Elsevier</source><creator>Sauter, E.R. ; Gwin, J.L. ; Mandel, J. ; Keller, S.M.</creator><creatorcontrib>Sauter, E.R. ; Gwin, J.L. ; Mandel, J. ; Keller, S.M.</creatorcontrib><description>Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53% of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread ( P = 0.06), and p53 expression correlated significantly ( P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC.</description><identifier>ISSN: 0960-7404</identifier><identifier>EISSN: 1879-3320</identifier><identifier>DOI: 10.1016/S0960-7404(10)80020-9</identifier><identifier>PMID: 7582188</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Biomarkers, Tumor - genetics ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - secondary ; Carcinoma, Non-Small-Cell Lung - surgery ; Carcinoma, Squamous Cell - genetics ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - secondary ; Carcinoma, Squamous Cell - surgery ; Disease Progression ; Disease-Free Survival ; Female ; Follow-Up Studies ; Forecasting ; Gene Expression Regulation, Neoplastic ; Genes, p53 - genetics ; Humans ; Incidence ; lung cancer ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Lung Neoplasms - surgery ; Lymph Node Excision ; Lymphatic Metastasis - genetics ; Male ; mediastinal lymph node dissection ; Middle Aged ; Neoplasm Staging ; p53 ; Pneumonectomy ; prognosis ; protein expression ; Survival Rate ; Treatment Outcome</subject><ispartof>Surgical oncology, 1995-06, Vol.4 (3), p.157-161</ispartof><rights>1995 Blackwell Science Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3</citedby><cites>FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7582188$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sauter, E.R.</creatorcontrib><creatorcontrib>Gwin, J.L.</creatorcontrib><creatorcontrib>Mandel, J.</creatorcontrib><creatorcontrib>Keller, S.M.</creatorcontrib><title>p53 and disease progression in patients with non-small cell lung cancer</title><title>Surgical oncology</title><addtitle>Surg Oncol</addtitle><description>Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53% of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread ( P = 0.06), and p53 expression correlated significantly ( P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC.</description><subject>Biomarkers, Tumor - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - secondary</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Carcinoma, Squamous Cell - genetics</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - secondary</subject><subject>Carcinoma, Squamous Cell - surgery</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Forecasting</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genes, p53 - genetics</subject><subject>Humans</subject><subject>Incidence</subject><subject>lung cancer</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - surgery</subject><subject>Lymph Node Excision</subject><subject>Lymphatic Metastasis - genetics</subject><subject>Male</subject><subject>mediastinal lymph node dissection</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>p53</subject><subject>Pneumonectomy</subject><subject>prognosis</subject><subject>protein expression</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0960-7404</issn><issn>1879-3320</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><recordid>eNqFkE9PAyEQxYnR1Fr9CE04GT2sDuwusCdjGq0mTTyoZ0JhWjEtW2Gr8dtL_6RXL0DmvZk3_AgZMrhhwMTtKzQCCllBdcXgWgFwKJoj0mdKNkVZcjgm_YPllJyl9AkAQnLWIz1ZK86U6pPxqi6pCY46n9AkpKvYziOm5NtAfaAr03kMXaI_vvugoQ1FWprFglrMx2Id5tSaYDGek5OZWSS82N8D8v748DZ6KiYv4-fR_aSwpYCuMA4rzk3jKuYUn-LMMYsSp1kUdcWEYNOZaxpW54eTAhnwSkklUSiuSmnLAbnczc17fq0xdXrp02YZE7BdJy2lhKqpymysd0Yb25QizvQq-qWJv5qB3gDUW4B6Q2dT2gLUTe4b7gPW0yW6Q9eeWNbvdjrmX357jDrZTMii8xFtp13r_0n4A3S0fs4</recordid><startdate>19950601</startdate><enddate>19950601</enddate><creator>Sauter, E.R.</creator><creator>Gwin, J.L.</creator><creator>Mandel, J.</creator><creator>Keller, S.M.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950601</creationdate><title>p53 and disease progression in patients with non-small cell lung cancer</title><author>Sauter, E.R. ; Gwin, J.L. ; Mandel, J. ; Keller, S.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Biomarkers, Tumor - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - secondary</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Carcinoma, Squamous Cell - genetics</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - secondary</topic><topic>Carcinoma, Squamous Cell - surgery</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Forecasting</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genes, p53 - genetics</topic><topic>Humans</topic><topic>Incidence</topic><topic>lung cancer</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - surgery</topic><topic>Lymph Node Excision</topic><topic>Lymphatic Metastasis - genetics</topic><topic>Male</topic><topic>mediastinal lymph node dissection</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>p53</topic><topic>Pneumonectomy</topic><topic>prognosis</topic><topic>protein expression</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sauter, E.R.</creatorcontrib><creatorcontrib>Gwin, J.L.</creatorcontrib><creatorcontrib>Mandel, J.</creatorcontrib><creatorcontrib>Keller, S.M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sauter, E.R.</au><au>Gwin, J.L.</au><au>Mandel, J.</au><au>Keller, S.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>p53 and disease progression in patients with non-small cell lung cancer</atitle><jtitle>Surgical oncology</jtitle><addtitle>Surg Oncol</addtitle><date>1995-06-01</date><risdate>1995</risdate><volume>4</volume><issue>3</issue><spage>157</spage><epage>161</epage><pages>157-161</pages><issn>0960-7404</issn><eissn>1879-3320</eissn><abstract>Present methods of predicting nodal progression preoperatively in patients with non-small cell lung cancer (NSCLC) are inadequate. Our hypothesis was that p53 expression in primary NSCLC would predict disease progression, making it a useful marker of adverse outcome. From 1987 to 1992, sixty-eight consecutive NSCLC patients underwent potentially curative lung resection and mediastinal lymph node dissection by one surgeon. Primary tumours were analysed using the p53 monoclonal antibody 1801. p53 overexpression was found in 53% of tumours. p53 expression did not correlate with age, gender, histology or stage. A trend toward a higher incidence of p53 expression was seen in tumours with nodal spread ( P = 0.06), and p53 expression correlated significantly ( P = 0.03) with improved disease-free survival in patients with squamous cell carcinoma (SCC). p53 was the fourth most important independent predictor of survival, behind histology, gender and nodal disease. As a weak independent predictor of survival, the correlation of p53 expression with survival in patients with SCC must be evaluated with caution. If borne out in a larger patient population, p53 expression may be a marker of nodal disease progression in patients with NSCLC.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>7582188</pmid><doi>10.1016/S0960-7404(10)80020-9</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0960-7404
ispartof Surgical oncology, 1995-06, Vol.4 (3), p.157-161
issn 0960-7404
1879-3320
language eng
recordid cdi_proquest_miscellaneous_77704943
source Elsevier
subjects Biomarkers, Tumor - genetics
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - secondary
Carcinoma, Non-Small-Cell Lung - surgery
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - pathology
Carcinoma, Squamous Cell - secondary
Carcinoma, Squamous Cell - surgery
Disease Progression
Disease-Free Survival
Female
Follow-Up Studies
Forecasting
Gene Expression Regulation, Neoplastic
Genes, p53 - genetics
Humans
Incidence
lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Lung Neoplasms - surgery
Lymph Node Excision
Lymphatic Metastasis - genetics
Male
mediastinal lymph node dissection
Middle Aged
Neoplasm Staging
p53
Pneumonectomy
prognosis
protein expression
Survival Rate
Treatment Outcome
title p53 and disease progression in patients with non-small cell lung cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T02%3A26%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=p53%20and%20disease%20progression%20in%20patients%20with%20non-small%20cell%20lung%20cancer&rft.jtitle=Surgical%20oncology&rft.au=Sauter,%20E.R.&rft.date=1995-06-01&rft.volume=4&rft.issue=3&rft.spage=157&rft.epage=161&rft.pages=157-161&rft.issn=0960-7404&rft.eissn=1879-3320&rft_id=info:doi/10.1016/S0960-7404(10)80020-9&rft_dat=%3Cproquest_cross%3E77704943%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c360t-ade422a9d41d82befd1ce7eb3606541661bfd991561bd76e10248787e682837c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=77704943&rft_id=info:pmid/7582188&rfr_iscdi=true